Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Apr 1;30(4):237-245.
doi: 10.1097/PAI.0000000000001009.

A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone

Monika D Polewski  1 , Gitte B Nielsen  1 , Ying Gu  1 , Aaron T Weaver  1 , Gavin Gegg  1 , Siena Tabuena-Frolli  1 , Mariana Cajaiba  1 , Debra Hanks  1 , Michael Method  2 , Michael F Press  3 , Claudia Gottstein  1 , Aaron M Gruver  2
Affiliations
Clinical Trial

A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone

Monika D Polewski et al. Appl Immunohistochem Mol Morphol. .

Abstract

The objectives were to develop a standardized Ki-67 immunohistochemistry (IHC) method for precise, robust, and reproducible assessment of patients with early breast cancer, and utilize this assay to evaluate patients participating in the monarchE study (NCT03155997). The Ki-67 assay was developed and validated for sensitivity, specificity, repeatability, precision, and robustness using a predefined ≥20% cutoff. Reproducibility studies (intersite and intrasite, interobserver and intraobserver) were conducted at 3 external laboratories using detailed scoring instructions designed for monarchE. Using the assay, patient tumors were classified as displaying high (≥20%) or low (<20%) Ki-67 expression; Kaplan-Meier methods evaluated 2-year invasive disease-free survival rates for these 2 groups among patients treated with endocrine therapy (ET) alone. All analytical validation and reproducibility studies achieved point estimates of >90% for negative, positive, and overall percent agreement. Intersite reproducibility produced point estimate values of 94.7%, 100.0%, and 97.3%. External interobserver reproducibility produced point estimate values of 98.9%, 97.8%, and 98.3%. Among 1954 patients receiving ET alone, 986 (50.5%) had high and 968 (49.5%) had low Ki-67 expression. Patients with high Ki-67 had a clinically meaningful increased risk of developing invasive disease within 2 years compared with those with low Ki-67 [2-y invasive disease-free survival rate: 86.1% (95% confidence interval: 83.1%-88.7%) vs. 92.0% (95% confidence interval: 89.7%-93.9%), respectively]. This standardized Ki-67 methodology resulted in high concordance across multiple laboratories, and its use in the monarchE study prospectively demonstrated the prognostic value of Ki-67 IHC in HR+, HER2- early breast cancer with high-risk clinicopathologic features.

PubMed Disclaimer

Conflict of interest statement

M.D.P. is an employee and company stockholder at Agilent Technologies; she also reports her spouse, Gregory Cherryholmes, is an employee and company stockholder for Agilent Technologies. G.B.N. is an employee and company stockholder at Agilent Technologies; she also reports her spouse, Jon St. Onge, is an employee and company stockholder at Agilent Technologies. Y.G. is former employee of Agilent technologies, and company stockholder. A.T.W. owns stock in Agilent Technologies. G.G. has nothing to disclose. S.T.-F. is an employee and company stockholder at Agilent Technologies. M.C. has nothing to disclose. M.M. is a former employee and minor company stockholder at Eli Lilly and Company, and a current employee at ImmunoGen; all work for this manuscript was completed while he was employed at Eli Lilly and Company. M.F.P. reports receiving honoraria from Science Branding Communications; serving on a Scientific Advisory Board and receiving consulting fees from Biocartis, Eli Lilly and Company, Merck, AstraZeneca, and Novartis; serving as a consultant with consulting fees from Zymeworks Inc; serving as a consultant and having private equity from TORL Biotherapeutics LLC; serving on a Medical Advisory Board and receiving consulting fees from Cepheid; and serving on a Pathology Advisory Board and receiving consulting fees from Eli Lilly and Company, USA. C.G. is an employee and company stockholder at Agilent Technologies. A.M.G. is an employee and company stockholder at Eli Lilly and Company; he also reports his spouse is an employee of Eli Lilly and Company. D.H. declares no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Key objectives of this study were to develop a precise, robust, and reproducible assay paired with clear interpretation guidance to reduce ambiguities in scoring. Training was provided to pathologists from different laboratories, resulting in high concordance between labs. This created a foundation for testing tumor proliferation using Ki-67 IHC in the monarchE phase 3 clinical trial. IHC indicates immunohistochemistry.
FIGURE 2
FIGURE 2
Expression levels in breast carcinoma tissue bank specimens stained with the investigational use only Ki-67 assay. Breast carcinoma specimen stained with Ki-67 primary antibody exhibiting both negative and weak positive staining. Negative cells showing gray staining defined as being below the threshold for positivity are indicated with black arrows. Cells with weak positive 1+ staining are indicated with green arrows (20× objective; scale bar is 50 μm).
FIGURE 3
FIGURE 3
Summary of percent agreement for assay external reproducibility studies performed at 3 external sites. Left 2 graphs demonstrate intersite and intrasite reproducibility, which measures assay staining and scoring interpretation. Right 2 graphs demonstrate inter- and intraobserver reproducibility, which measures scoring interpretation only. Horizontal dashed lines indicate acceptance criteria for the external reproducibility studies. CI indicates confidence interval; OA, overall percent agreement; NPA, negative percent agreement; PPA positive percent agreement.
FIGURE 4
FIGURE 4
LOESS plot of external reproducibility interobserver Ki-67 continuous scores grouped by observer. LOESS lines demonstrate average trends over interobserver data using locally weighted regression. IHC indicates immunohistochemistry; LOESS, locally estimated scatterplot smoothing.
FIGURE 5
FIGURE 5
Kaplan-Meier plot demonstrating the prognostic value of the assay in the monarchE phase 3 study. Among patients with high clinicopathologic risk factors, patients whose tumors displayed high Ki-67 (≥20%) had an even greater risk of recurrence than those with low Ki-67 tumors (<20%); 2-year IDFS rate: 86.1% (95% confidence interval: 83.1-88.7) versus 92.0% (95% confidence interval: 89.7-93.9), respectively. ET indicates endocrine therapy.
See this image and copyright information in PMC

References

    1. Smith I, Robertson J, Kilburn L, et al. . Long-term outcome and prognostic value of Ki-67 after periopertative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21:1443–1454. - PMC - PubMed
    1. Nielsen TO, Leung SC, Rimm DL, et al. . Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113:808–819. - PMC - PubMed
    1. Dickler MN, Tolaney SM, Rugo HS, et al. . MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res. 2017;23:5218–5224. - PMC - PubMed
    1. Johnston S, Martin M, Di Leo A, et al. . MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. - PMC - PubMed
    1. Sledge GW, Jr, Toi M, Neven P, et al. . MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–2884. - PubMed

Publication types

Associated data